The Latest in Precision Medicine and Lung Cancer

SMALL_PM webchat screenshot

Even before President Barack Obama declared it a national initiative, precision medicine has helped bring more effective treatment to patients with many types of cancer. One disease that has benefited from these treatments is lung cancer, where targeted therapies have significantly improved outcomes for patients. “When we find we have drugs targeted for a specific genetic mutation driving the cancer, the chance of having someone live longer and feel better is much higher,” says David Jackman, MD, a medical oncologist with Dana-Farber’s Lowe Center for Thoracic Oncology and the institute’s Medical Director for Clinical Pathways. “We’re doubling, tripling, and in …

Continue reading

Promising Research Developments Stir Hopes for Melanoma, Lung, Breast and Ovarian Cancer

F. Stephen Hodi, MD

The growing excitement about the potential of immunotherapy treatments for cancer continued at the 2015 meeting of the American Association for Cancer Research (AACR), one of the largest cancer research meetings of the year. Several Dana-Farber investigators presented encouraging results of immunotherapy for melanoma, lung cancer, and breast cancer. F. Stephen Hodi, MD, and Leena Gandhi, MD, gave reports on recently published results for immunotherapy trials in melanoma and lung cancer, respectively. Their findings were simultaneously published in the New England Journal of Medicine. “This field has changed a lot in the past few years and even in the past …

Continue reading

Running Boston: ‘The Only Way I Know How’

SMALL_RunDFMC Page

By Eric Kaye If you were living under a rock this winter… that is, a rock buried by seven feet of snow like most people around Boston, here is what you might have missed. The Patriots won the Super Bowl, Zayn Malik left One Direction, and Boston set an all-time record for snowfall. Also, somewhere hidden behind the snow banks that narrowed the city sidewalks, runners were training for the Boston Marathon. This is my 8th year repeating a ritual march from Hopkinton to Boston on the third Monday in April. All eight Boston Marathons run the only way I …

Continue reading

How Integrative Therapies Can Help Lung Cancer Patients

Massage

Any cancer diagnosis and treatment can take a physical and emotional toll on patient. For many lung cancer patients, post-operative pain and muscle tension, as well as breathing and sleeping issues, are common side effects. To help ease some of these symptoms, patients can seek out integrative therapies, which can be used in conjunction with standard treatment. “Patients who participate in integrative therapies may experience fewer side effects of treatment and therefore, have a better quality of life,” says Bambi Mathay, MD, LMT, oncology massage therapist and reiki master practitioner at Dana-Farber’s Leonard P. Zakim Center for Integrative Therapies. Lung cancer …

Continue reading

Five Things Nonsmokers Need to Know About Lung Cancer

SOG_1634_08

Lung cancer remains the most deadly form of cancer in the United States, with nearly 160,000 deaths annually and more than 224,000 new cases expected in 2014. While many lung cancer diagnoses are linked to smoking, nonsmokers can develop the disease as well and should be aware of their risks. Anyone can get lung cancer. Although smoking is the leading risk factor for lung cancer, anyone with lungs is susceptible to this disease. Air pollution and exposure to asbestos, radon, chromium, nickel, arsenic, soot, or tar are also causes. Individuals who have been treated with radiation therapy to the chest …

Continue reading

Latest Research Shows Progress in Fight Against Lung Cancer

SOG_7976_11

Lung cancer, which causes more deaths worldwide than any other malignancy, is revealing its vulnerabilities under a sustained assault from science. Many of the most recent advances against the disease have a long pedigree at Dana-Farber. It was 10 years ago, in fact, that Dana-Farber scientists and elsewhere showed non-small cell lung cancers that carry a mutation in the gene EGFR are susceptible to a targeted drug. That discovery, which ushered in the era of personalized medicine for lung cancer, has lengthened the lives of tens of thousands of patients around the world. Today it is a standard procedure in …

Continue reading

ASCO: New Advances in Ovarian, Prostate, Lung and Melanoma Treatment

SOG_5604_10SMALL

“Science and Society” was the theme of this year’s American Society of Clinical Oncology (ASCO) 50th annual meeting. The meeting showcased  cancer research from around the world. Some new findings from Dana-Farber researchers included: Joyce Liu, MD, MPH, of the Susan F. Smith Center for Women’s Cancers reported that, in a phase 2 clinical trial, a combination of olaparib (a drug that blocks DNA repair in cancer cells) and cediranib (which blocks blood vessel growth in tumors) was considerably more effective in women with recurrent ovarian cancer than olaparib alone.. Progression-free survival – the length of time after treatment when …

Continue reading

Five Things You Need to Know About Men’s Health/Cancer Screenings

SOG_7048_12

Cancer affects thousands of men across the United States every year, with the most common diagnoses coming in the form of prostate, colon, testicular, lung, and skin cancer. Not all cancers can be detected early on, but for some forms of the disease, the spread of cancer can be prevented through screenings. As June marks Men’s Health/Cancer Awareness Month, here are five things you need to know about men’s health screenings:   1. Prostate Cancer One in every six men is affected by prostate cancer, which most often affects men over age 50. In addition, age, family history, diet and lifestyle, …

Continue reading

Precision Medicine for Lung Cancer Marks Tenth Anniversary

4.30.14 Lung CancerSmall

Ten years ago researchers at Dana-Farber and in Japan published a study showing that lung cancer patients whose tumors had a malfunctioning version of a protein called Epidermal Growth Factor Receptor (EGFR) responded dramatically to a drug that specifically targets the EGFR protein. The findings launched the era of precision medicine for lung cancer, transforming the way the disease is treated in many patients. Today, the arsenal of targeted therapies for lung adenocarcioma – the most common lung malignancy – includes more than a dozen agents, some of which have received Food and Drug Administration (FDA) approval and some of …

Continue reading